This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Five Dumbest Things on Wall Street This Week: June 29

5. Ventrus Gets Flushed

The 60% drop in shares Ventrus Biosciences (VTUS) on Monday is certainly agonizing for the company's investors but for one Wall Street analyst, it's a huge pain in the ass.

Shares of the biotech plummeted to $5 from $12 on the news that its experimental hemorrhoid drug, titled VEN 309, flunked a costly late-stage trial. According to Ventrus, which went public in December 2010, the highly touted drug failed to adequately stop anal bleeding in its test subjects and therefore the company plans to stop the fiscal bleeding by halting its development.

Now that VEN 309 is history, Ventrus plans to allocate its remaining $31.1 million in cash toward the completion of its drug for anal fissures, named VEN 307, and fecal incontinence.

(Look, we're sorry, but this is what we do. It's what adolescents, frat boys and the Farrelly Brothers do too, but still we have no choice!)

Anyway, of all the analysts who follow the stock, it was Brean Murray Carret analyst Jonathan Aschoff (Oh man! Aschoff!?! Lord, please forgive us) who got totally caught with his pants down. Not even two weeks ago, Aschoff initiated coverage of Ventrus with a glowing buy rating and a $30 price target based on his belief that VEN 309 would pass FDA muster and then go on to generate about $1 billion in annual sales at its "peak market penetration."

Sadly, because of the drug's demise, Ventrus investors can forget about that particular penetration. And, as you may have guessed, Aschoff was forced to flush that particular outlook down the you-know-where Monday, lowering his target to $11 soon after the stock hit the fan.

Nevertheless, despite all that's happened, Aschoff is still not giving up hope that someday the shares will indeed turn into shinola. He reiterated his buy rating and told investors to "buy the dip" because he believes VEN 307 has the ability to pick up where VEN 309 left off.

Oh man. We sure do hope his latest call pays off, because right now it doesn't look like he knows his VEN 309 from his elbow.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,912.11 -70.48 -0.42%
S&P 500 1,969.95 -8.96 -0.45%
NASDAQ 4,442.6980 -2.2110 -0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs